Nerium oleander distillate improves fat and glucose metabolism in high-fat diet-fed streptozotocin-induced diabetic rats

International Journal of Endocrinology

Volumn 2012, Issue , 2012, Pages

  Bas, Ahmet Levent ^a   Demirci, Sule ^b   Yazihan, Nuray ^c   Uney, Kamil ^a   Ermis Kaya, Ezgi ^c  

^a SELCUK UNIVERSITY   (Turkey)

^b MEHMET AKIF ERSOY UNIVERSITY   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FAT; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; MALE; NERIUM OLEANDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES;

EID: 84871380149     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2012/947187     Document Type: Article

References (47)

1. Özcan U., Cao Q., Yilmaz E., Lee A. H., Iwakoshi N. N., Özdelen E., Tuncman G., Görgün C., Glimcher L. H., Hotamisligil G. S., Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004 306 5695 457 461 2-s2.0-5644231992 10.1126/science.1103160 (Pubitemid 39372439)
2. Mlinar B., Marc J., Janež A., Pfeifer M., Molecular mechanisms of insulin resistance and associated diseases. Clinica Chimica Acta 2007 375 1-2 20 35 2-s2.0-33750041947 10.1016/j.cca.2006.07.005 (Pubitemid 44584240)
3. Evans J. L., Goldfine I. D., Maddux B. A., Grodsky G. M., Are oxidative stress: activated signaling pathways mediators of insulin resistance and β -cell dysfunction? Diabetes 2003 52 1 1 8 2-s2.0-0037219409 10.2337/diabetes.52. 1.1 (Pubitemid 36042100)
4. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z. W., Karin M., Shoelson S. E., Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk β Science 2001 293 5535 1673 1677 2-s2.0-0035979775 10.1126/science.1061620 (Pubitemid 32807849)
5. Eckel R. H., Grundy S. M., Zimmet P. Z., The metabolic syndrome. The Lancet 2005 365 9468 1415 1428 2-s2.0-17144380822 10.1016/S0140-6736(05)66378-7 (Pubitemid 40523737)
6. Bays H., Atherogenic dyslipidaemia in type 2 diabetes and metabolic syndrome: current and future treatment options. British Journal of Diabetes and Vascular Disease 2003 3 5 356 360 2-s2.0-0242319795 (Pubitemid 37336995)
7. WHO, Library cataloguing-in-publication data diabetes action now. An initiative of the World Health Organization and the International Diabetes Federation, 2004
8. Yeh G. Y., Eisenberg D. M., Kaptchuk T. J., Phillips R. S., Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003 26 4 1277 1294 2-s2.0-0042668497 10.2337/diacare.26.4.1277 (Pubitemid 36929285)
9. Oubré A. Y., Carlson T. J., King S. R., Reaven G. M., From plant to patient: an ethnomedical approach to the identification of new drugs for the treatment of NIDDM. Diabetologia 1997 40 5 614 617 2-s2.0-0030903290 10.1007/s001250050724 (Pubitemid 27186801)
10. Begum S., Siddiqui B. S., Sultana R., Zia A., Suria A., Bio-active cardenolides from the leaves of Nerium oleander. Phytochemistry 1999 50 3 435 438 2-s2.0-0345059829 10.1016/S0031-9422(98)00523-8 (Pubitemid 29035496)
11. Adome R. O., Gachihi J. W., Onegi B., Tamale J., Apio S. O., The cardiotonic effect of the crude ethanolic extract of Nerium oleander in the isolated guinea pig hearts. African health sciences 2003 3 2 77 82 2-s2.0-4844230004
12. Wang X., Plomley J. B., Newman R. A., Cisneros A., LC/MS/MS analyses of an oleander extract for cancer treatment. Analytical Chemistry 2000 72 15 3547 3552 2-s2.0-0034254818 (Pubitemid 30614930)
13. Ishikawa A., Yamashita H., Hiemori M., Inagaki E., Kimoto M., Okamoto M., Tsuji H., Memon A. N., Mohammadi A., Natori Y., Characterization of inhibitors of postprandial hyperglycemia from the leaves of Nerium indicum. Journal of Nutritional Science and Vitaminology 2007 53 2 166 173 2-s2.0-34250618361 10.3177/jnsv.53.166 (Pubitemid 46933027)
14. Srinivasan K., Viswanad B., Asrat L., Kaul C. L., Ramarao P., Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacological Research 2005 52 4 313 320 2-s2.0-23844504364 10.1016/j.phrs.2005.05.004 (Pubitemid 41175991)
15. Matthews D. R., Hosker J. P., Rudenski A. S., Naylor B. A., Treacher D. F., Turner R. C., Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 7 412 419 2-s2.0-0021813187 (Pubitemid 15018832)
16. Coetzee C., Levendal R. A., van de Venter M., Frost C. L., Anticoagulant effects of a cannabis extract in an obese rat model. Phytomedicine 2007 14 5 333 337 2-s2.0-34247497684 10.1016/j.phymed.2006.02.004 (Pubitemid 46654786)
17. Shamoon H., Duffy H., Fleischer N., Engel S., Saenger P., Strelzyn M., Litwak M., Wylie-Rosett J., Farkash A., Geiger D., Engel H., Fleischman J., Pompi D., Ginsberg N., Glover M., Brisman M., Walker E., Thomashunis A., Gonzalez J., The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993 329 14 977 986 2-s2.0-0027370108 10.1056/NEJM199309303291401 (Pubitemid 23307905)
18. Creager M. A., Lüscher T. F., Cosentino F., Beckman J. A., Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003 108 12 1527 1532 2-s2.0-0141615827 10.1161/01.CIR.0000091257.27563.32 (Pubitemid 37176462)
19. Basta G., Schmidt A. M., de Caterina R., Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovascular Research 2004 63 4 582 592 2-s2.0-4043058031 10.1016/j.cardiores.2004.05.001 (Pubitemid 39078671)
20. Snieder H., Sawtell P. A., Ross L., Walker J., Spector T. D., Leslie R. D. G., HbA1c levels are genetically determined even in type 1 diabetes: evidence from healthy and diabetic twins. Diabetes 2001 50 12 2858 2863 2-s2.0-0035653627 (Pubitemid 33733139)
21. ADA, Standards of medical care in diabetes. Diabetes Care 2004 27 S15 S35 2-s2.0-3042796194
22. Bonora E., Formentini G., Calcaterra F., Lombardi S., Marini F., Zenari L., Saggiani F., Poli M., Perbellini S., Raffaelli A., Cacciatori V., Santi L., Targher G., Bonadonna R., Muggeo M., HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the verona diabetes complications study. Diabetes Care 2002 25 7 1135 1141 2-s2.0-0036633043 10.2337/diacare.25.7.1135 (Pubitemid 41071163)
23. Chahil T. J., Ginsberg H. N., Diabetic dyslipidemia. Endocrinology and Metabolism Clinics of North America 2006 35 3 491 510 2-s2.0-33748415924 10.1016/j.ecl.2006.06.002 (Pubitemid 44339576)
24. Ginsberg H. N., Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes 1996 45 3 supplement S27 S30 2-s2.0-0029883048
25. Tan M. H., Johns D., Glazer N. B., Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clinical Chemistry 2004 50 7 1184 1188 2-s2.0-3042562177 10.1373/clinchem.2004.031757 (Pubitemid 38824226)
26. Alexander C. M., Landsman P. B., Teutsch S. M., Haffner S. M., NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003 52 5 1210 1214 2-s2.0-0037407403 10.2337/diabetes.52.5.1210 (Pubitemid 36523358)
27. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D. S. J., Haffner S. M., Isles C., Macfarlane P. W., Packard C. J., Cobbe S. M., Shepherd J., Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation 2003 108 4 414 419 2-s2.0-0042665536 10.1161/01.CIR. 0000080897.52664.94 (Pubitemid 36935533)
28. Brinton E. A., Eisenberg S., Breslow J. L., Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. Journal of Clinical Investigation 1991 87 2 536 544 2-s2.0-0026073753
29. Packard C. J., Shepherd J., Lipoprotein heterogeneity and apolipoprotein B metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology 1997 17 12 3542 3556 2-s2.0-0031458498 (Pubitemid 28028567)
30. Hanak V., Munoz J., Teague J., Stanley A. Jr., Bittner V., Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. The American Journal of Cardiology 2004 94 2 219 222 2-s2.0-3142640803 10.1016/j.amjcard.2004.03.069 (Pubitemid 38902877)
31. Mclaughlin T., Reaven T., Abbasi F., Lamendola C., Saad M., Waters D., Simon J., Krauss R. M., Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? American Journal of Cardiology 2005 96 3 399 404 2-s2.0-23044477108 10.1016/j.amjcard.2005.03.085 (Pubitemid 41058868)
32. Jia L., Long S., Fu M., Yan B., Tian Y., Xu Y., Gou L., Relationship between total cholesterol/high-density lipoprotein cholesterol ratio, triglyceride/high-density lipoprotein cholesterol ratio, and high-density lipoprotein subclasses. Metabolism 2006 55 9 1141 1148 2-s2.0-33747136208 10.1016/j.metabol.2006.04.004 (Pubitemid 44219052)
33. da Luz P. L., Favarato D., Faria-Neto J. R. Jr., Lemos P., Chagas A. C. P., High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics 2008 63 4 427 432 2-s2.0-50449085440 10.1590/S1807- 59322008000400003
34. Schwartz S., Raskin P., Fonseca V., Graveline J. F., Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. New England Journal of Medicine 1998 338 13 861 866 2-s2.0-0032568310 10.1056/NEJM199803263381302 (Pubitemid 28135962)
35. Banks W. A., Coon A. B., Robinson S. M., Moinuddin A., Shultz J. M., Nakaoke R., Morley J. E., Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 2004 53 5 1253 1260 2-s2.0-2342449315 10.2337/diabetes.53.5.1253 (Pubitemid 38569011)
36. Angulo P., Lindor K. D., Non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2002 17 1 supplement S186 S190 2-s2.0-0036103602 10.1046/j.1440-1746.17.s1.10.x (Pubitemid 34539308)
37. Ruhl C. E., Everharty J. E., Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003 124 1 71 79 2-s2.0-0037221394 10.1053/gast.2003. 50004 (Pubitemid 36055340)
38. Ioannou G. N., Weiss N. S., Boyko E. J., Kahn S. E., Lee S. P., Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 2005 128 3 627 635 2-s2.0-15744377647 10.1053/j.gastro.2004.12.004 (Pubitemid 40585365)
39. Hanley A. J. G., Wagenknecht L. E., Festa A., D'Agostino R. B., Haffner S. M., Alanine aminotransferase and directly measured insulin sensitivity in a multiethnic cohort: the insulin resistance atherosclerosis study. Diabetes Care 2007 30 7 1819 1827 2-s2.0-34447125597 10.2337/dc07-0086 (Pubitemid 47036358)
40. Oz S. G., Guven G. S., Kilicarslan A., Calik N., Beyazit Y., Sozen T., Evaluation of bone metabolism and bone mass in patients with type-2 diabetes mellitus. Journal of the National Medical Association 2006 98 10 1598 1604 2-s2.0-33750583084 (Pubitemid 44682952)
41. Thompson C. S., Kuwana T., Rosalki S. B., Mikhailidis D. P., Changes in serum alkaline phosphatase isoenzymes associated with diabetes mellitus, fasting and aging in the rat. International Journal of Diabetes 1993 1 31 39
42. Puig A., Jimenez-Liñan M., Lowell B. B., Hamann A., Hu E., Spiegelman B., Flier J. S., Moller D. E., Regulation of PPAR γ gene expression by nutrition and obesity in rodents. Journal of Clinical Investigation 1996 97 11 2553 2561 2-s2.0-0030000088 (Pubitemid 26187343)
43. Escher P., Braissant O., Basu-Modak S., Michalik L., Wahli W., Desvergne B., Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001 142 10 4195 4202 2-s2.0-0034801882 10.1210/en.142.10.4195 (Pubitemid 32907045)
44. Vidal-Puig A. J., Considine R. V., Jimenez-Liñan M., Werman A., Pories W. J., Caro J. F., Flier J. S., Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. Journal of Clinical Investigation 1997 99 10 2416 2422 2-s2.0-0030977450 (Pubitemid 27227719)
45. Yki-Järvinen H., Thiazolidinediones. New England Journal of Medicine 2004 351 11 1106 1118 2-s2.0-19244365650 10.1056/NEJMra041001 (Pubitemid 39167514)
46. Pyper S. R., Viswakarma N., Yu S., Reddy J. K., PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nuclear receptor signaling 2010 8 e002 2-s2.0-77954987061
47. Wang Y. X., Lee C. H., Tiep S., Yu R. T., Ham J., Kang H., Evans R. M., Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 2003 113 2 159 170 2-s2.0-0037453718 10.1016/S0092- 8674(03)00269-1 (Pubitemid 36514968)